Showing results (41-50 of 118) with videos related to

Sort By:
Pageof 12
Anticancer Research|September 21, 2012
A randomized controlled non-inferiority study comparing the antiemetic effect between intravenous granisetron and oral azasetron based on estimated 5-HT3 receptor occupancyJunki Endo, Hirotoshi Iihara, Maya Yamada, et al.
Future Oncology (London, England)|August 9, 2025
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomitingRudolph M Navari, Timothy Tyler, Naoki Inui, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 13, 2025
Efficacy of triplet antiemetic prophylaxis against chemotherapy-induced nausea and vomiting in patients with soft tissue sarcomas receiving consecutive-day doxorubicin and ifosfamide therapyYunami Yamada, Hirotoshi Iihara, Akihito Nagano, et al.
Cancer Chemotherapy and Pharmacology|June 8, 2026
Fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in oxaliplatin-based regimens: a prospective observational study (LODEC-N)Yohei Iimura, Hirotoshi Iihara, Takeshi Aoyama, et al.
Anticancer Research|July 7, 2021
Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic CancerKoichi Ohata, Hironori Fujii, Shiori Sadaka, et al.
Diagnostic Microbiology and Infectious Disease|June 14, 2006
Emerging multiple mutations and high-level fluoroquinolone resistance in methicillin-resistant Staphylococcus aureus isolated from ocular infectionsHirotoshi Iihara, Takashi Suzuki, Yoshiaki Kawamura, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancerHideki Hayashi, Hirotoshi Iihara, Chiemi Hirose, et al.
Anticancer Research|January 9, 2021
Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI Plus Bevacizumab or AfliberceptYunami Yamada, Nobuhisa Matsuhashi, Hironori Fujii, et al.
International Journal of Clinical Oncology|April 11, 2021
Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenibDaichi Watanabe, Hironori Fujii, Yunami Yamada, et al.
The Oncologist|March 13, 2020
Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective StudyHironori Fujii, Nobuhisa Matsuhashi, Mika Kitahora, et al.
Pageof 12